CURE

FDA Grants Fast Track to ART6043 for BRCA-Mutated Advanced Breast Cancer

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

Hims hair loss review: Cost, how it works, and who it’s good for

A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age 35. So, while Hims provides access to a number of different prescription ...

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

PDUFA action date set for August 23, 2026If approved, DTX401 will be the first treatment to address the underlying cause of GDSIaNOVATO, Calif., ...

What Pressure Does to an Athlete’s Body

Those of us who watch the Olympics as bystanders tend to smugly judge athletes for succumbing to pressure without ...
Nagaland Post

Why eating fibre is good for your brain

Eating fibre can improve health, lengthen lifespans, and even protect our brains. Yet many of us are still coming up short on this “essential nutrient”.A diet high in wholegrains, fruits, pulses, nuts ...
Stocktwits on MSN

Rare stock edges up on priority review for gene therapy in rare metabolic disorder

The FDA is now expected to decide on the application by Aug. 23. ・The company intends to manufacture the therapy at its new gene therapy manufacturing facility in Bedford, Massachusetts, if approved.
The Manila Times

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...

Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen ...

PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmace ...

Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD

TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) protein through a one-time, durable ...
Opinion
Le LézardOpinion

Women's Health Company Mira Calls for Federal Reform of U.S. Sex Education

Mira, a leading hormonal health company, today announced the launch of a national petition aimed at closing a dramatic gap around hormonal health in sex education in the United States, aligning with ...
Newspoint on MSN

From grade 2 fatty liver to almost normal in 6 months! No medication, no supplements, just two lifestyle changes your doctor prescribed

How To Reverse Fatty Liver: If not taken care of in time, the problem of fatty liver can later turn into serious conditions ...
Open Heart

Impact of invasive coronary function testing on management of ANOCA patients and secondary care resource utilisation: insights from a multicentre retrospective study in the UK

Background Invasive coronary function testing (CFT) is indicated in patients with refractory angina with non-obstructed coronary arteries (ANOCA). Despite this, questions remain regarding patient ...